37859-25-9

Basic information

• Product Name: 2-(2-Naphthyl)acetyl chloride
• Synonyms: BUTTPARK 52\15-93;2-(2-NAPHTHYL)ACETYL CHLORIDE;NAPHTHALEN-2-YL-ACETYL CHLORIDE;2-Naphth-2-ylacetyl chloride;2-(2-Naphthyl)acetyl chloride, tech;2-Naphthaleneacetylchloride;2-Naphthylacetyl chloride;(Naphth-2-yl)acetyl chloride
• CAS NO: 37859-25-9
• Molecular Formula: C₁₂H₉ClO
• Molecular Weight: 204.65
• Mol File: 37859-25-9.mol

Chemical Properties

• Melting Point: 61-65°C
• Boiling Point: 333.7 °C at 760 mmHg
• Flash Point: 156.4 °C
• Appearance: /
• Density: 5 g/cm3
• Vapor Pressure: 0.000134mmHg at 25°C
• Refractive Index: 1.628
• CAS DataBase Reference: 2-(2-Naphthyl)acetyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-Naphthyl)acetyl chloride(37859-25-9)
• EPA Substance Registry System: 2-(2-Naphthyl)acetyl chloride(37859-25-9)

Safety Data

• Hazard Codes: C,Xi
• Statements: 34-36
• Safety Statements: 26-36/37/39-45
• RIDADR: 3261
• Hazardous Substances Data: 37859-25-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-Naphthyl)acetyl chloride is used as a key intermediate for the synthesis of various pharmaceutical substances. Its reactivity allows it to form amide and ester linkages, which are crucial in the construction of complex drug molecules. This makes it an essential component in the development of new medications and the improvement of existing ones.
Used in Chemical Intermediates:
In the chemical industry, 2-(2-Naphthyl)acetyl chloride is employed as a versatile building block for the synthesis of a range of chemical intermediates. Its ability to react with various functional groups makes it a valuable asset in the production of specialty chemicals, such as dyes, pigments, and other organic compounds.
Used in Research and Development:
2-(2-Naphthyl)acetyl chloride is also used in academic and industrial research settings as a reagent for exploring new chemical reactions and pathways. Its unique reactivity provides opportunities for the discovery of novel compounds and the advancement of synthetic methodologies. This makes it an indispensable tool for chemists working on the cutting edge of chemical research.

InChI:InChI=1/C12H9ClO/c13-12(14)8-9-5-6-10-3-1-2-4-11(10)7-9/h1-7H,8H2

Upstream product

• 581-96-4 2-naphthylacetic acid 
• 93579-03-4 tert-butyl α-(naphthalen-2-yl)acetate 
• 93-08-3 methyl 2-naphthyl ketone 
• 114373-76-1 N-<2-(2-Naphthyl)-1-thioxoethyl>piperidine 

Downstream Products

• 182492-41-7 3-Oxo-4-(2-naphthyl)-butanoic acid ethyl ester 
• 201802-02-0 N-[5-(2,4-Dioxo-thiazolidin-5-ylmethyl)-2-hydroxy-phenyl]-2-naphthalen-2-yl-acetamide 
• 7498-57-9 2-naphthaleneacetonitrile 
• 708276-20-4 2-(2-naphthyl)-1-(4-methylsulfanylphenyl)ethanone 
• 100597-64-6 2-[1-Naphthalen-2-yl-meth-(Z)-ylidene]-4-[1-p-tolyl-meth-(E)-ylidene]-[1,3]oxathiolan-5-one 
• 100597-83-9 2-[1-Naphthalen-2-yl-meth-(E)-ylidene]-3-oxo-4-[1-p-tolyl-meth-(Z)-ylidene]-3λ⁴-[1,3]oxathiolan-5-one 
• 100597-74-8 4-(4-Methyl-benzyl)-2-naphthalen-2-ylmethyl-[1,3]oxathiolan-5-one 
• 954105-07-8 {3-[(2-naphthalen-2-yl-acetyl)(benzyloxy)amino]propyl}phosphonic acid dibenzyl ester 
• 1186621-62-4 5-[(β-naphthylmethyl)carbonyl]amino-8-(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine 
• 1600530-05-9 4-(2-(2-(naphthalen-2-yl)acetamido)benzamido)butanoic acid 

Relevant articles and documents

Synthesis and evaluation of benzenesulfonic acid derivatives as human neutrophil elastase (hNE) inhibitors

Herein we report our investigation concerning the development of Human neutrophil elastase (hNE) inhibitors for the treatment of Acute Respiratory Distress Syndrome (ARDS). Various benzenesulfonic acid derived compounds were synthesized and evaluated as competitive inhibitors of hNE. Biological screening revealed that compound 4f shows moderate inhibitory activity (IC50 = 35.2 μM) against hNE. Compound 4f was also superimposed onto the active center of hNE to understand the binding mode.

Photoredox Catalyzed Sulfonylation of Multisubstituted Allenes with Ru(bpy)3Cl2 or Rhodamine B

A highly regio- and stereoselective sulfonylation of allenes was developed that provided direct access to α, β-substituted unsaturated sulfone. By means of visible-light photoredox catalysis, the free radicals produced by p-toluenesulfonic acid reacted with multisubstituted allenes to obtain Markovnikov-type vinyl sulfones with Ru(bpy)3Cl2 or Rhodamine B as photocatalyst. The yield of this reaction could reach up to 91%. A series of unsaturated sulfones would be used for further transformation to some valuable compounds.

SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28

The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, and to a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier. The disclosure also relates to a method of treating a disease or disorder associated with ubiquitin-specific protease 28 (USP28) a method of treating cancer, and a method of inhibiting USP28, comprising administering to a subject in need thereof a compound of formula (I).

Novel Pyridine-Based Hydroxamates and 2′-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity

Starting from the N-hydroxy-3-(4-(2-phenylbutanoyl)amino)phenyl)acrylamide (5 b) previously described by us as a HDAC inhibitor, we prepared four aza-analogues, 6–8, 9 b, as regioisomers containing the pyridine nucleus. Preliminary screening against mHDAC1 highlighted the N-hydroxy-5-(2-(2-phenylbutanoyl)amino)pyridyl)acrylamide (9 b) as the most potent inhibitor. Thus, we further developed both pyridylacrylic- and nicotinic-based hydroxamates (9 a, 9 c–f, and 11 a–f) and 2′-aminoanilides (10 a–f and 12 a–f), related to 9 b, to be tested against HDACs. Among them, the nicotinic hydroxamate 11 d displayed sub-nanomolar potency (IC50: 0.5 nM) and selectivity up to 34 000 times that of HDAC4 and from 100 to 1300 times that of all the other tested HDAC isoforms. The 2′-aminoanilides were class I-selective HDAC inhibitors, generally more potent against HDAC3, with the nicotinic anilide 12 d being the most effective (IC50HDAC3=0.113 μM). When tested in U937 leukemia cells, the hydroxamates 9 e, 11 c, and 11 d blocked over 80 % of cells in G2/M phase, whereas the anilides did not alter cell-cycle progress. In the same cell line, the hydroxamate 11 c and the anilide 10 b induced about 30 % apoptosis, and the anilide 12 c displayed about 40 % cytodifferentiation. Finally, the most potent compounds in leukemia cells 9 b, 11 c, 10 b, 10 e, and 12 c were also tested in K562, HCT116, and A549 cancer cells, displaying antiproliferative IC50 values at single-digit to sub-micromolar level.

Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.

The organocatalytic enantiodivergent fluorination of β-ketodiaryl-phosphine oxides for the construction of carbon-fluorine quaternary stereocenters

Commercially available cinchona alkaloids that can catalyze the enantiodivergent fluorination of β-ketodiarylphosphine oxides were developed to construct carbon-fluorine quaternary stereocenters. This protocol features a wide scope of substrates and excellent enantioselectivities, and it is scalable.

METHOD FOR MANUFACTURING AROMATIC NITRILE COMPOUND

The present invention provides a method for industrially producing a highly pure aromatic nitrile compound and a highly pure aromatic carboxylic acid compound safely and highly efficiently at low costs. Compound (2) is subjected to Willgerodt reaction in the presence of an additive as necessary, and the obtained amide compound (3) is hydrolyzed and neutralized to give carboxylic acid compound (4). Carboxylic acid compound (4) is reacted with a halogenating agent in the presence of a catalyst as necessary in an organic solvent, and further reacted with an amidating agent, and the obtained amide compound (5) or (6) is reacted with a dehydrating agent to give nitrile compound (1). Alternatively, carboxylic acid compound (4) is reacted with a halogenating agent and a compound represented by the formula R6SO2R7 in the presence of a catalyst as necessary in an organic solvent to give nitrile compound (1). Np is a naphthyl group optionally having substituent(s), R5 is an alkylene group having 1-3 carbon atoms, and other symbols are as described in the DESCRIPTION.

Photoinduced Diverse Reactivity of Diazo Compounds with Nitrosoarenes

A diverse reactivity of diazo compounds with nitrosoarene in an oxygen-transfer process and a formal [2 + 2] cycloaddition is reported. Nitosoarene has been exploited as a mild oxygen source to oxidize an in situ generated carbene intermediate under visible-light irradiation. UV-light-mediated in situ generated ketenes react with nitosoarenes to deliver oxazetidine derivatives. These operationally simple processes exemplify a transition-metal-free and catalyst-free protocol to give structurally diverse α-ketoesters or oxazetidines.

Quantitative activity-activity relationship (QAAR) driven design to develop hydroxamate derivatives of pentanoic acids as selective HDAC8 inhibitors: synthesis, biological evaluation and binding mode of interaction studies

Histone deacetylase 8 (HDAC8) has been implicated as a potential drug target of many diseases including cancer. HDAC8 isoform selectivity over other class-I HDACs is a major concern nowadays. In this work, a series of pentanoic acid based hydroxamates wit